Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity.

May 1, 2024·
Chuan Qin
,
Min Zhang
,
Da-Peng Mou
,
Luo-Qi Zhou
,
Ming-Hao Dong
,
Liang Huang
,
Wen Wang
,
Song-Bai Cai
,
Yun-Fan You
,
Ke Shang
,
Jun Xiao
,
Di Wang
,
Chun-Rui Li
,
Yi Hao
,
Michael Heming
,
Long-Jun Wu
,
Gerd Meyer Zu Hörste
,
Chen Dong
,
Bi-Tao Bu
,
Dai-Shi Tian
,
Wei Wang
· 0 min read
Abstract
Chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of neurological autoimmune diseases is promising, but CAR T cell kinetics and immune alterations after treatment are poorly understood. Here, we performed single-cell multi-omics sequencing of paired cerebrospinal fluid (CSF) and blood samples from patients with neuromyelitis optica spectrum disorder (NMOSD) treated with anti-B cell maturation antigen (BCMA) CAR T cells. Proliferating cytotoxic-like CD8+ CAR T cell clones were identified as the main effectors in autoimmunity. Anti-BCMA CAR T cells with enhanced features of chemotaxis efficiently crossed the blood-CSF barrier, eliminated plasmablasts and plasma cells in the CSF, and suppressed neuroinflammation. The CD44-expressing early memory phenotype in infusion products was potentially associated with CAR T cell persistence in autoimmunity. Moreover, CAR T cells from patients with NMOSD displayed distinctive features of suppressed cytotoxicity compared with those from hematological malignancies. Thus, we provide mechanistic insights into CAR T cell function in patients with neurological autoimmune disease.
Type
Publication
Science Immunology